Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated

Life After Treatment: Monitoring and Survivorship

At a Glance

Life after GIST treatment involves regular monitoring with CT scans to check for recurrence, typically every 3 to 6 months initially. Many patients also take long-term targeted medications like imatinib, which require active management of side effects and routine blood tests.

Transitioning into the survivorship phase of GIST can bring a mix of relief and anxiety. Because GIST is a chronic condition for many, “life after treatment” often involves long-term medication and a lifetime of monitoring. Understanding what to expect during this phase can help you navigate the road ahead with confidence.

The Surveillance Roadmap

Monitoring for recurrence is a standard part of GIST care. Doctors primarily use CT scans of the abdomen and pelvis to look for signs of the cancer returning [1][2]. If GIST does recur, it most commonly appears in the liver or the peritoneum (the lining of the abdominal cavity) [3][4].

While schedules vary based on your individual risk score, a typical surveillance plan often follows this pattern [5][6]:

  • Years 1–3: Scans every 3 to 6 months (this is the period of highest risk).
  • Years 4–5: Scans every 6 to 12 months.
  • Year 5 and beyond: Annual scans for high-risk patients.

Living with Long-Term TKI Therapy

Many high-risk and some intermediate-risk patients remain on imatinib (Gleevec) for three years or longer to prevent recurrence. If your tumor was classified as low-risk, you will likely not need this preventative (adjuvant) medication and can just be monitored with scans [7].

While generally well-tolerated, taking a Tyrosine Kinase Inhibitor (TKI) for a long period can cause chronic side effects that require management [8]:

  • Digestive Issues: Mild nausea or diarrhea are common. A crucial daily tip: always take your TKI medication with a large meal and a full glass of water to significantly reduce nausea and stomach upset [9].
  • Fluid Retention: You may notice puffiness around the eyes or swelling in the ankles [10].
  • Anemia: Long-term use can sometimes lead to a drop in red blood cells, causing fatigue [11].
  • Kidney Health: Imatinib can cause a slow decline in kidney function over time, so your doctor will monitor your blood work regularly [12][13].

Managing the Financial Reality

Because you might be on these medications for years, the financial burden can be a major concern for patients. Do not let costs quietly derail your care. Ask your oncology team or social worker to connect you with patient assistance programs or co-pay navigators, which exist specifically to help cover the costs of these expensive targeted therapies.

Navigating “Scanxiety”

It is completely normal to feel a surge of stress before a scheduled scan—a phenomenon the survivor community calls scanxiety [14]. This anxiety often peaks in the “waiting period” between the scan and receiving the results [15].

Strategies to manage this include:

  • Scheduling: Request that your follow-up appointment be as close to the scan time as possible to minimize the wait [16].
  • Mindfulness: Focusing on the present moment rather than future “what-ifs” has been shown to help reduce distress [17].
  • Education: Understanding that GIST is highly treatable even if it does return can sometimes take the “edge” off the fear [18].

Tips for Long-Term Wellness

Survivorship is about more than just scans; it is about maintaining your quality of life.

  1. Be Your Own Historian: Keep a log of your side effects. Something that feels “minor” like fatigue or muscle cramps can often be improved with small medical adjustments [19].
  2. Stay Vigilant, Not Vigilante: While you should report new, persistent abdominal pain or changes in bowel habits, remember that most “aches and pains” are not cancer [20].
  3. Find Your Community: Because GIST is rare, connecting with other patients through advocacy groups can provide invaluable practical tips for living well on TKIs.

Common questions in this guide

How often will I need CT scans after GIST treatment?
Your scan schedule depends on your recurrence risk. Typically, patients have CT scans of the abdomen and pelvis every 3 to 6 months for the first three years, every 6 to 12 months for years four and five, and annually thereafter.
How long will I need to take imatinib (Gleevec) after my initial treatment?
Patients with an intermediate or high risk of recurrence often remain on imatinib for three years or longer to prevent the tumor from returning. If your tumor was classified as low-risk, you may not need this medication and will just be monitored with scans.
What are the long-term side effects of TKI medications like imatinib?
Chronic use of TKIs can cause mild nausea, diarrhea, fluid retention around the eyes or ankles, and fatigue due to anemia. It can also cause a slow decline in kidney function, which your doctor will monitor regularly through blood work.
How can I reduce stomach upset when taking my GIST medication?
You can significantly reduce nausea and stomach upset by always taking your TKI medication with a large meal and a full glass of water.
What are the most common signs that GIST has returned?
If a gastrointestinal stromal tumor recurs, it most commonly appears in the liver or the peritoneum, which is the lining of the abdominal cavity. You should report any new, persistent abdominal pain or changes in bowel habits to your doctor.
How can I manage scanxiety before my follow-up scans?
Scanxiety is completely normal. You can manage this stress by asking to have your scan results reviewed on the same day as your appointment, practicing mindfulness, and remembering that GIST remains highly treatable even if it does return.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific surveillance schedule (e.g., every 3, 6, or 12 months) are you recommending for my risk level?
  2. 2.Can we arrange for my scan results to be reviewed and shared with me on the same day as the scan?
  3. 3.Are there specific blood tests, such as kidney function or hemoglobin, that we should monitor regularly while I am on long-term imatinib?
  4. 4.Since GIST typically recurs in the liver or peritoneum, are there specific symptoms I should watch for between my scheduled scans?
  5. 5.Can you connect me with a social worker or financial navigator to help with the costs of long-term TKI medication?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Gastrointestinal stromal tumors: a comprehensive radiological review.

    Inoue A, Ota S, Yamasaki M, et al.

    Japanese journal of radiology 2022; (40(11)):1105-1120 doi:10.1007/s11604-022-01305-x.

    PMID: 35809209
  2. 2

    Acute abdomen due to a perforated giant GIST of the small intestine evolving slowly for 6 years: A case report.

    Ben Mahmoud A, Hammami M, Atri S, et al.

    International journal of surgery case reports 2025; (129()):111207 doi:10.1016/j.ijscr.2025.111207.

    PMID: 40147204
  3. 3

    Gastrointestinal stromal tumor metastasis to the ovary: A case report.

    Yamaguchi T, Kinoshita J, Saito H, et al.

    SAGE open medical case reports 2021; (9()):2050313X211012511 doi:10.1177/2050313X211012511.

    PMID: 34017592
  4. 4

    Two cases of gastrointestinal stromal tumor of the small intestine with liver and bone metastasis.

    Aktan M, Koc M, Yavuz BB, Kanyilmaz G

    Annals of translational medicine 2015; (3(17)):259 doi:10.3978/j.issn.2305-5839.2015.09.46.

    PMID: 26605305
  5. 5

    NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.

    von Mehren M, Kane JM, Riedel RF, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(11)):1204-1214 doi:10.6004/jnccn.2022.0058.

    PMID: 36351335
  6. 6

    The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.

    Nishida T, Blay JY, Hirota S, et al.

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2016; (19(1)):3-14 doi:10.1007/s10120-015-0526-8.

    PMID: 26276366
  7. 7

    Adjuvant systemic therapy for small bowel gastrointestinal stromal tumor (GIST): Is there a survival benefit after R0 resection?

    Patel DJ, Lutfi W, Eguia E, et al.

    Surgery 2020; (168(4)):695-700 doi:10.1016/j.surg.2020.04.069.

    PMID: 32713755
  8. 8

    Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

    Hochhaus A, Larson RA, Guilhot F, et al.

    The New England journal of medicine 2017; (376(10)):917-927 doi:10.1056/NEJMoa1609324.

    PMID: 28273028
  9. 9

    Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.

    Hino A, Yoshida H, Tada Y, et al.

    International journal of hematology 2016; (104(5)):605-611 doi:10.1007/s12185-016-2071-6.

    PMID: 27460678
  10. 10

    Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.

    Haguet H, Douxfils J, Mullier F, et al.

    Expert opinion on drug safety 2017; (16(1)):5-12 doi:10.1080/14740338.2017.1261824.

    PMID: 27852118
  11. 11

    Hemoglobin changes during long-lasting frontline treatment with Tyrosine-Kinase inhibitors in patients with chronic myeloid leukemia.

    Latagliata R, Carmosino I, Di Veroli A, et al.

    Leukemia & lymphoma 2026; (67(2)):349-354 doi:10.1080/10428194.2025.2586816.

    PMID: 41246876
  12. 12

    Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.

    Sakurai M, Kikuchi T, Karigane D, et al.

    International journal of hematology 2019; (109(3)):292-298 doi:10.1007/s12185-019-02596-z.

    PMID: 30680668
  13. 13

    Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.

    Ren X, Qin Y, Huang X, et al.

    Annals of hematology 2019; (98(7)):1627-1640 doi:10.1007/s00277-019-03690-2.

    PMID: 31089794
  14. 14

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  15. 15

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  16. 16

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  17. 17

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  18. 18

    Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.

    Huang WK, Wu CE, Wang SY, et al.

    Current treatment options in oncology 2022; (23(9)):1303-1319 doi:10.1007/s11864-022-00996-8.

    PMID: 35976553
  19. 19

    Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.

    Kwak JY, Kim SH, Oh SJ, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(23)):7180-7188 doi:10.1158/1078-0432.CCR-17-0957.

    PMID: 28939746
  20. 20

    Gastrointestinal Stromal Tumor (GIST) Causing Obscure Gastrointestinal Bleeding: An Uncommon Way of Diagnosing An Uncommon Disease.

    Dziadkowiec KN, Stawinski P, Sánchez-Luna SA, Katz A

    Cureus 2020; (12(8)):e9558 doi:10.7759/cureus.9558.

    PMID: 32905491

This page provides educational information about GIST survivorship and monitoring. Always consult your oncology team for your specific surveillance schedule and medication management.

Get notified when new evidence is published on Gastrointestinal stromal tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.